Iván Sánchez Fernández1, Nicholas S Abend1, Satish Agadi1, Sookee An1, Ravindra Arya1, James Nicholas Brenton1, Jessica L Carpenter1, Kevin E Chapman1, William D Gaillard1, Tracy A Glauser1, Howard P Goodkin1, Kush Kapur1, Mohamad A Mikati1, Katrina Peariso1, Margie Ream1, James Riviello1, Robert C Tasker1, Tobias Loddenkemper2. 1. From the Division of Epilepsy and Clinical Neurophysiology, Department of Neurology (I.S.F., S. An, K.K., T.L.), and the Division of Critical Care, Departments of Neurology, Anesthesiology, Perioperative and Pain Medicine (R.C.T.), Boston Children's Hospital, Harvard Medical School, MA; the Department of Child Neurology (I.S.F.), Hospital Sant Joan de Déu, University of Barcelona, Spain; the Division of Neurology (N.S.A.), The Children's Hospital of Philadelphia, The Perelman School of Medicine at the University of Pennsylvania; the Section of Neurology and Developmental Neuroscience, Department of Pediatrics (S. Agadi), Baylor College of Medicine, Houston, TX; the Comprehensive Epilepsy Center (R.A., T.A.G.), Division of Neurology (K.P.), Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH; the Departments of Neurology and Pediatrics (J.N.B., H.P.G.), The University of Virginia Health System, Charlottesville; the Department of Epilepsy, Neurophysiology, and Critical Care Neurology (J.L.C., W.D.G.), Children's National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC; the Departments of Pediatrics and Neurology (K.E.C.), Children's Hospital Colorado, University of Colorado School of Medicine, Aurora; the Division of Pediatric Neurology (M.A.M.), Duke University Medical Center, Duke University, Durham, NC; the Division of Neurocritical Care (K.P.), University of Cincinnati Medical Center, OH; the Division of Pediatric Neurology (M.R.), Nationwide Children's Hospital, The Ohio State University, Columbus; and the Division of Child Neurology (J.R.), Columbia University Medical Center, Columbia University, New York, NY. 2. From the Division of Epilepsy and Clinical Neurophysiology, Department of Neurology (I.S.F., S. An, K.K., T.L.), and the Division of Critical Care, Departments of Neurology, Anesthesiology, Perioperative and Pain Medicine (R.C.T.), Boston Children's Hospital, Harvard Medical School, MA; the Department of Child Neurology (I.S.F.), Hospital Sant Joan de Déu, University of Barcelona, Spain; the Division of Neurology (N.S.A.), The Children's Hospital of Philadelphia, The Perelman School of Medicine at the University of Pennsylvania; the Section of Neurology and Developmental Neuroscience, Department of Pediatrics (S. Agadi), Baylor College of Medicine, Houston, TX; the Comprehensive Epilepsy Center (R.A., T.A.G.), Division of Neurology (K.P.), Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH; the Departments of Neurology and Pediatrics (J.N.B., H.P.G.), The University of Virginia Health System, Charlottesville; the Department of Epilepsy, Neurophysiology, and Critical Care Neurology (J.L.C., W.D.G.), Children's National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC; the Departments of Pediatrics and Neurology (K.E.C.), Children's Hospital Colorado, University of Colorado School of Medicine, Aurora; the Division of Pediatric Neurology (M.A.M.), Duke University Medical Center, Duke University, Durham, NC; the Division of Neurocritical Care (K.P.), University of Cincinnati Medical Center, OH; the Division of Pediatric Neurology (M.R.), Nationwide Children's Hospital, The Ohio State University, Columbus; and the Division of Child Neurology (J.R.), Columbia University Medical Center, Columbia University, New York, NY. tobias.loddenkemper@childrens.harvard.edu.
Abstract
OBJECTIVE: To describe the time elapsed from onset of pediatric convulsive status epilepticus (SE) to administration of antiepileptic drug (AED). METHODS: This was a prospective observational cohort study performed from June 2011 to June 2013. Pediatric patients (1 month-21 years) with convulsive SE were enrolled. In order to study timing of AED administration during all stages of SE, we restricted our study population to patients who failed 2 or more AED classes or needed continuous infusions to terminate convulsive SE. RESULTS: We enrolled 81 patients (44 male) with a median age of 3.6 years. The first, second, and third AED doses were administered at a median (p25-p75) time of 28 (6-67) minutes, 40 (20-85) minutes, and 59 (30-120) minutes after SE onset. Considering AED classes, the initial AED was a benzodiazepine in 78 (96.3%) patients and 2 (2-3) doses of benzodiazepines were administered before switching to nonbenzodiazepine AEDs. The first and second doses of nonbenzodiazepine AEDs were administered at 69 (40-120) minutes and 120 (75-296) minutes. In the 64 patients with out-of-hospital SE onset, 40 (62.5%) patients did not receive any AED before hospital arrival. In the hospital setting, the first and second in-hospital AED doses were given at 8 (5-15) minutes and 16 (10-40) minutes after SE onset (for patients with in-hospital SE onset) or after hospital arrival (for patients with out-of-hospital SE onset). CONCLUSIONS: The time elapsed from SE onset to AED administration and escalation from one class of AED to another is delayed, both in the prehospital and in-hospital settings.
OBJECTIVE: To describe the time elapsed from onset of pediatric convulsive status epilepticus (SE) to administration of antiepileptic drug (AED). METHODS: This was a prospective observational cohort study performed from June 2011 to June 2013. Pediatric patients (1 month-21 years) with convulsive SE were enrolled. In order to study timing of AED administration during all stages of SE, we restricted our study population to patients who failed 2 or more AED classes or needed continuous infusions to terminate convulsive SE. RESULTS: We enrolled 81 patients (44 male) with a median age of 3.6 years. The first, second, and third AED doses were administered at a median (p25-p75) time of 28 (6-67) minutes, 40 (20-85) minutes, and 59 (30-120) minutes after SE onset. Considering AED classes, the initial AED was a benzodiazepine in 78 (96.3%) patients and 2 (2-3) doses of benzodiazepines were administered before switching to nonbenzodiazepine AEDs. The first and second doses of nonbenzodiazepine AEDs were administered at 69 (40-120) minutes and 120 (75-296) minutes. In the 64 patients with out-of-hospital SE onset, 40 (62.5%) patients did not receive any AED before hospital arrival. In the hospital setting, the first and second in-hospital AED doses were given at 8 (5-15) minutes and 16 (10-40) minutes after SE onset (for patients with in-hospital SE onset) or after hospital arrival (for patients with out-of-hospital SE onset). CONCLUSIONS: The time elapsed from SE onset to AED administration and escalation from one class of AED to another is delayed, both in the prehospital and in-hospital settings.
Authors: Syndi Seinfeld; Shlomo Shinnar; Shumei Sun; Dale C Hesdorffer; Xiaoyan Deng; Ruth C Shinnar; Kathryn O'Hara; Douglas R Nordli; L Matthew Frank; William Gallentine; Solomon L Moshé; John M Pellock Journal: Epilepsia Date: 2014-02-06 Impact factor: 5.864
Authors: Robert Silbergleit; Valerie Durkalski; Daniel Lowenstein; Robin Conwit; Arthur Pancioli; Yuko Palesch; William Barsan Journal: N Engl J Med Date: 2012-02-16 Impact factor: 91.245
Authors: Stuart Lewena; Victoria Pennington; Jason Acworth; Susan Thornton; Peter Ngo; Shona McIntyre; David Krieser; Jocelyn Neutze; Deirdre Speldewinde Journal: Pediatr Emerg Care Date: 2009-02 Impact factor: 1.454
Authors: Richard J Burman; Joshua S Selfe; John Hamin Lee; Maurits van den Berg; Alexandru Calin; Neela K Codadu; Rebecca Wright; Sarah E Newey; R Ryley Parrish; Arieh A Katz; Jo M Wilmshurst; Colin J Akerman; Andrew J Trevelyan; Joseph V Raimondo Journal: Brain Date: 2019-11-01 Impact factor: 13.501
Authors: Juma S Mbwana; Zachary M Grinspan; Russell Bailey; Madison Berl; Jeffrey Buchhalter; Adrian Bumbut; Zach Danner; Tracy Glauser; Angie Glotstein; Howard Goodkin; Brian Jacobs; Lisa Jones; Barbara Kroner; Gardiner Lapham; Tobias Loddenkemper; Demetrius M Maraganore; Doug Nordli; William D Gaillard Journal: Neurol Clin Pract Date: 2019-02
Authors: Marina Gaínza-Lein; Iván Sánchez Fernández; Michele Jackson; Nicholas S Abend; Ravindra Arya; J Nicholas Brenton; Jessica L Carpenter; Kevin E Chapman; William D Gaillard; Tracy A Glauser; Joshua L Goldstein; Howard P Goodkin; Kush Kapur; Mohamad A Mikati; Katrina Peariso; Robert C Tasker; Dmitry Tchapyjnikov; Alexis A Topjian; Mark S Wainwright; Angus Wilfong; Korwyn Williams; Tobias Loddenkemper Journal: JAMA Neurol Date: 2018-04-01 Impact factor: 18.302
Authors: Robert C Tasker; Howard P Goodkin; Iván Sánchez Fernández; Kevin E Chapman; Nicholas S Abend; Ravindra Arya; James N Brenton; Jessica L Carpenter; William D Gaillard; Tracy A Glauser; Joshua Goldstein; Ashley R Helseth; Michele C Jackson; Kush Kapur; Mohamad A Mikati; Katrina Peariso; Mark S Wainwright; Angus A Wilfong; Korwyn Williams; Tobias Loddenkemper Journal: Pediatr Crit Care Med Date: 2016-10 Impact factor: 3.624
Authors: Ryan P Williams; Brenda Banwell; Robert A Berg; Dennis J Dlugos; Maureen Donnelly; Rebecca Ichord; Sudha Kilaru Kessler; Jane Lavelle; Shavonne L Massey; Jennifer Hewlett; Allison Parker; Alexis A Topjian; Nicholas S Abend Journal: Epilepsia Date: 2016-03-07 Impact factor: 5.864